SecBot SecBot
Biotech Drug Report Generated Nov 14, 2026

SwitchGuard

NSPR·InspireMD Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Pivotal Study (CGUARDIANS III IDE)
Time to market
The CGUARDIANS III pivotal study began enrolling in June 2026 with no disclosed completion date. The company targets a U.S. commercial launch in 2027 if the study succeeds and FDA approval follows, but this timeline is aspirational and subject to clinical results and regulatory review.
Why 4/10
SwitchGuard has no hard dated catalyst (PDUFA, pivotal readout, or AdComm) scheduled in the next ~12 months. The CGUARDIANS III pivotal study began enrolling in June 2026 but no completion or data-readout date has been disclosed. The company targets a U.S. commercial launch in 2027 if approved, which is aspirational. ImpactScore is set to 4 (default) because the defining binary events are too distant to drive a near-term share-price move for this specific asset.
Actionable Insight NEUTRAL

SwitchGuard is an early-stage pipeline asset with no hard dated catalyst in the next 12 months. The CGUARDIANS III pivotal study began enrolling in June 2026; watch for enrollment completion updates or interim data announcements, but no timeline has been disclosed. The stock's near-term moves will be driven by the just-approved CGuard Prime TCAR commercial launch and the company's ability to execute after the recent delivery-system recall and dilutive $37.5M offering.

Price Chart

Loading chart...

Executive Summary

SwitchGuard is a neuroprotection shunt system being developed by InspireMD (Nasdaq: NSPR) for use during Transcarotid Artery Revascularization (TCAR) procedures to prevent stroke by filtering debris from blood flow. It is in the CGUARDIANS III pivotal study, which received FDA IDE approval in May 2026 and enrolled its first patient in June 2026. The company targets a U.S. commercial launch in 2027 if approved. SwitchGuard faces established competition from Silk Road Medical's ENROUTE system, which is already on the market. For InspireMD, the more immediate value driver is the just-approved (Nov 12, 2026) CGuard Prime TCAR indication, which doubles the U.S. addressable market for its stent platform. The stock has been under pressure from a recent delivery-system recall, withdrawn 2026 guidance, and a dilutive $37.5M public offering priced on Nov 13, 2026.

How It Works

SwitchGuard is a neuroprotection system (a shunt with blood flow indicators) used during Transcarotid Artery Revascularization (TCAR), a minimally invasive procedure to open blocked carotid arteries in the neck. During TCAR, the surgeon makes a small incision in the neck and inserts a tube directly into the carotid artery. The SwitchGuard system shunts blood flow away from the brain during the procedure and filters it to catch any debris (emboli) that could break loose, preventing it from traveling to the brain and causing a stroke. It is designed to work alongside InspireMD's CGuard Prime carotid stent system.

Trial Status

The CGUARDIANS III pivotal study received FDA Investigational Device Exemption (IDE) approval in May 2026, and the first patient was enrolled in June 2026. The study evaluates the safety and efficacy of the SwitchGuard Neuro Protection System for use in TCAR procedures alongside the CGuard Prime 80 cm stent platform. No enrollment completion or data readout date has been disclosed.

The Two-Sided Case

▲ Bull Case4
SwitchGuard addresses a clear unmet need: a neuroprotection shunt for TCAR procedures that works with InspireMD's own CGuard Prime stent platform, potentially offering a combined solution versus competitors' separate components.
The FDA approved the IDE for the CGUARDIANS III pivotal study in May 2026, and the first patient was enrolled in June 2026, showing regulatory and clinical momentum.
InspireMD just received FDA approval for CGuard Prime in TCAR (Nov 12, 2026), which approximately doubles the U.S. addressable market for its stent platform and creates a natural cross-sell opportunity for SwitchGuard if approved.
Analyst consensus shows 8 Buy/Strong Buy ratings vs 1 Hold (Nov 2026), with a mean price target of $3.33 versus the current ~$0.59 price, implying significant upside if the company executes.
▼ Bear Case4
SwitchGuard is still in an early-stage pivotal study (CGUARDIANS III) with no completion or readout date disclosed; a U.S. commercial launch is targeted for 2027 at the earliest, years away.
Silk Road Medical's ENROUTE Transcarotid Neuroprotection System PLUS is already on the market and established in TCAR procedures, giving it a first-mover advantage.
InspireMD's recent voluntary recall of its CGuard Prime 135cm delivery system (May 2026) and withdrawal of 2026 revenue guidance raised execution concerns, and the company just priced a dilutive $37.5M public offering (Nov 13, 2026).
The stock has fallen sharply (down ~17% on Nov 13 alone to $0.64 regular session, $0.59 post-market) amid the offering and general market skepticism about the company's near-term prospects.

Upcoming Catalysts

  • CGUARDIANS III pivotal study enrollment completion update (no date disclosed)
  • Potential interim or topline data from CGUARDIANS III (no date disclosed)
  • Planned PMA supplement submission for enhanced CGuard Prime for CAS procedures (targeting December 2026)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

InspireMD, Inc. 424B5 NSPR ·Originating report

Sources · 6

Hover a chip for the title
1 manilatimes.net2 markets.businessinsider.com3 evtoday.com4 mddionline.com5 markets.businessinsider.com6 fool.com